Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

Systemic Lupus Erythematosus

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus

Lupus.

Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y

doi: 10.1177/0961203317749047.

Systemic Lupus Erythematosus

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

Arthritis Res Ther.

Sohrabian A, Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J

doi: 10.1186/s13075-019-2056-y.

Spinal Disorders

Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment

Rheumatology (Oxford)

Björk A, Da Silva Rodrigues R, Richardsdotter Andersson E, Ramírez Sepúlveda JI, Mofors J, Kvarnström M, Oke V, Svenungsson E, Gunnarsson I, Wahren-Herlenius M

doi: 10.1093/rheumatology/keaa611

Systemic Lupus Erythematosus

Response to ustekinumab treatment in patients with systemic lupus erythematosus is linked to suppression of serum interferon gamma levels

Arthritis Rheumatol

Cesaroni M, Seridi L, Loza MJ, Schreiter J, Sweet K, Franks C, Ma K, Orillion A, Campbell K, Gordon R, Branigan P, Lipsky P, van Vollenhoven R, Hahn BH, Tsokos GC, Chevrier M, Rose S, Baribaud F, Jordan J

doi: 10.1002/art.41547

Systemic Lupus Erythematosus

Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus

Front Immunol.

Nehring J, Schirmbeck LA, Friebus-Kardash J, Dubler D, Huynh-Do U, Chizzolini C, Ribi C, Trendelenburg M

doi: 10.3389/fimmu.

Autoimmune Disease

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Autoimmun Rev.

Bragazzi NL, McGonagle D, Watad S, Adawi M, Mahroum N, Damiani G, Conic R, Bridgewood C, Mahagna H, Giacomelli L, Eggenhöffner R, Mahamid M, Pigatto PDM, Amital H, Watad A

doi: 10.1016/j.autrev.2018.08.002.

Psoriasis

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

J Eur Acad Dermatol Venereol.

Reich K, Blauvelt A, Armstrong A, Langley RG, de Vera A, Kolbinger F, Spindeldreher S, Ren M, Bruin G

doi: 10.1111/jdv.15637.

Systemic Lupus Erythematosus

Impact of multiple sclerosis on quality of life: Comparison with systemic lupus erythematosus

Clin Neurol Neurosurg.

Carnero Contentti E, Genco ND, Hryb JP, Caspi M, Chiganer E, Di Pace JL, López PA, Lessa C, Caride A, Perassolo M

doi: 10.1016/

Systemic Lupus Erythematosus

An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus.

Rheumatol Ther.

Thakral A, Klein-Gitelman MS

doi: 10.1007/s40744-016-0044-0.

Related content

Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment

Response to ustekinumab treatment in patients with systemic lupus erythematosus is linked to suppression of serum interferon gamma levels

Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus

Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

Impact of multiple sclerosis on quality of life: Comparison with systemic lupus erythematosus

An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus.